• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomePatients & FamiliesSupport for HCM

Support for HCM

Committed to people and their families living with Hypertrophic Cardiomyopathy

What is HCM?

HCM is the most commonly inherited form of heart disease that is chronic and progressive in nature. People with HCM may have a higher risk of heart failure, stroke, and atrial fibrillation. Commonly experienced symptoms include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood. This is known as “diastolic dysfunction.”

If you or a loved one have been diagnosed with cardiovascular disease and are experiencing any of the symptoms described above, talk to your doctor about genetic testing for HCM.

Medicines are available for HCM, but people taking may experience limited efficacy, undesirable safety concerns, inconvenient dosing, side effects, and the need for frequent monitoring. While progress has been made for the HCM community, new therapeutic approaches are needed.

Learn more about HCM Clinical Trials

Resources

Hypertrophic Cardiomyopathy Association

Hypertrophic Cardiomyopathy Association (HCMA)

The preeminent organization improving the lives of those with hypertrophic cardiomyopathy preventing untimely deaths and advancing global understanding.

Learn More About HCMA

How do others live with HCM?

Meet Lindsay.

Patient Advocate. Author. Volunteer.
Living with HCM.

    • Read her story

Edgewise Clinical Trials in HCM

About CIRRUS-HCM, the Phase 2 clinical trial for HCM

We are recruiting a Phase 2 trial of EDG-7500 in HCM patients. There are advantages and disadvantages to participating in a clinical trial. Talk to your doctor or explore the links below to learn more about whether CIRRUS-HCM is right for you.

  • Learn about the CIRRUS-HCM trial
  • Learn about EDG-7500

WHAT IS EDG-7500?

EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, intended to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with obstructive and non-obstructive HCM, and with other diseases of diastolic dysfunction. EDG-7500 is currently in clinical trials in individuals with HCM.

Learn more about EDG-7500

Explore Clinical Trials

EDG-7500 is an investigational therapy that has not been approved for use in hypertrophic cardiomyopathy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts